WASHINGTON — Federal officers on Thursday permitted a brand new sort of ache capsule designed to eradicate the dangers of dependancy and overdose related to opioid medicines like Vicodin and OxyContin.
The U.S. Meals and Drug Administration mentioned it permitted Vertex Prescription drugs’ Journavx for short-term ache that always follows surgical procedure or accidents.
It is the primary new pharmaceutical strategy to treating ache in additional than 20 years, providing a substitute for each opioids and over-the-counter medicines like ibuprofen and acetaminophen. However the medicine’s modest effectiveness and prolonged growth course of underscore the challenges of discovering new methods to handle ache.
Research in additional than 870 sufferers with acute ache as a consequence of foot and belly surgical procedures confirmed Vertex’s drug supplied extra reduction than a dummy capsule however did not outperform a typical opioid-acetaminophen mixture capsule.
“It isn’t a slam dunk on effectiveness,” mentioned Michael Schuh of the Mayo Clinic, a pharmacist and ache drugs skilled who was not concerned within the analysis. “However it’s a slam dunk in that it is a very totally different pathway and mechanism of motion. So, I believe that reveals quite a bit promise.”
The brand new drug will carry an inventory worth of $15.50 per capsule, making it many instances dearer than comparable opioids, which are sometimes accessible as generics for $1 or much less.
Vertex started researching the drug within the 2000s, when overdoses had been rocketing upward, principally pushed by mass prescribing of opioid painkillers for frequent illnesses like arthritis and again ache. Prescriptions have fallen sharply within the final decade and the present wave of the opioid epidemic is especially as a consequence of illicit fentanyl, not pharmaceutical medicines.
Opioids scale back ache by binding to receptors within the mind that obtain nerve indicators from totally different elements of the physique. These chemical interactions additionally give rise to opioids’ addictive results.
Vertex’s drug works in a different way, blocking proteins that set off ache indicators which can be later despatched to the mind.
“In making an attempt to develop medicines that do not have the addictive dangers of opioid medicines, a key issue is working to dam ache signaling earlier than it will get to the mind,” Vertex’s Dr. David Altshuler, informed The Related Press final yr.
Generally reported negative effects with the drug had been nausea, constipation, itching, rash and headache.
“The brand new medicine has aspect impact profiles which can be inherently, not solely totally different, however do not contain the danger of substance abuse and different key negative effects related to opioids,” mentioned Dr. Charles Argoff of the Albany Medical Middle, who consulted for Vertex on the drug’s growth.
The preliminary idea to give attention to pain-signaling proteins got here out of analysis involving individuals with a uncommon hereditary situation that causes insensitivity to ache.
Vertex has attracted curiosity from Wall Avenue for its formidable drug pipeline that includes profitable FDA approval for a number of medicine throughout a number of types of power ache, which usually represents a much bigger monetary alternative than acute ache.
However the Boston drugmaker’s share worth plummeted in December when Vertex reported disappointing mid-stage ends in a research of sufferers with power nerve ache affecting the decrease again and legs. The drug did not carry out considerably higher than placebo, the analysis discovered.
“We imagine the information replicate a close to worst-case state of affairs for this key pipeline program,” biotechnology analyst Brian Abrahams mentioned in a analysis notice to traders, including that the outcomes jeopardized estimates that Vertex’s pipeline may very well be value billions throughout a number of types of ache.
Nonetheless, Vertex executives mentioned they plan to maneuver ahead with a brand new, late-stage research of the drug, theorizing {that a} totally different trial design may yield higher outcomes and pave the best way for FDA approval in power ache.
Copyright © 2025 by The Related Press. All Rights Reserved.
